An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease
KL1333 2025-104B
Phase 2 other active
Quick answer
An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease for Adult patients with primary mitochondrial disease is a Phase 2 program (other) at Pharming Technologies B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharming Technologies B.V.
- Indication
- Adult patients with primary mitochondrial disease
- Phase
- Phase 2
- Modality
- other
- Status
- active